Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anavex Life Sciences has screened first subject in a randomized, placebo-controlled, dose-escalating ANAVEX 2-73 Phase I clinical study in alzheimer's patients.
Subscribe to our email newsletter
ANAVEX 2-73 is a new class of oral, disease-modifying drug being studied to potentially treat alzheimer’s disease itself, versus treating its symptoms.
The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of ANAVEX 2-73 to determine the maximally tolerated dose in humans.
Anavex executive chairman Cameron Durrant said they are excited that the first human study for ANAVEX 2-73 is underway.
"ANAVEX 2-73 has been more than a decade in the making, so this event marks a great milestone for our company," Durrant said.